Here's a look at some of the top regulatory stories for medical device companies this week: Inside the Medtronic-Covidien deal: Contrasting styles brought the companies together; Medtronic and Covidien prepare 1st Integration Summit; FTC approves Cerner's $1.3B Siemens health IT buy; Alere unveils $3.82B privatization plan; Medtronic, Covidien slide on new U.S. inversion rules
New rules on inversion mergers announced yesterday by the U.S. Treasury Dept. send shares of Medtronic and Covidien down as questions swirl about the impact ion their pending $43 billion merger.
Merging medtech titans Medtronic and Covidien are preparing to host the 1st of 4 Integration Summits, scheduled later this month.
A senior executive at Medtronic, vice president of corporate development Chris Cleary, explains how Covidien played "scrappy" upstart all the way to a $43 billion payout.
Covidien begins enrolling patients in clinical trials for its Pipeline embolization system as well as all its endovascular stroke devices.
Covidien (NYSE:COV) announced today that it enrolled the 1st patients in a pair of clinical trials evaluating the company's neurovascular technologies.
Washington D.C. is preparing to move on efforts to penalize companies that move their headquarters overseas to benefit from lower corporate tax rates.
Covidien penetrates home-based patient monitoring through an agreement licensing its ZephyrLIFE telehealth solutions to Geneia for integration into their @Home platform.
Medtech titan Covidien (NYSE:COV) is breaching new ground in home care with its ZephyrLIFE remote monitoring platform, agreeing to license the technology to healthcare solutions company Geneia.